GRAIL Inc.
GRAL
Rangering i aksjer
#3037
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early... GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Aksjekurs
$132.85
Sist synkronisert: 2026-10-21
Markedsverdi
$5.93B
Endring (1 dag)
6.56%
Endring (1 år)
66.56%
Land
US
Handel GRAIL Inc. (GRAL)
Kategori
Healthcare
EPS for GRAIL Inc. (GRAL)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til GRAIL Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for GRAIL Inc. fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2025 | $-11.11 | -82.51% |
| 2024 | $-63.54 | 34.62% |
| 2023 | $-47.20 | -72.85% |
| 2022 | $-173.87 | 332.73% |
| 2021 | $-40.18 | 1,494.44% |
| 2020 | $-2.52 | 26.63% |
| 2019 | $-1.99 | -17.77% |
| 2018 | $-2.42 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
